nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—breast cancer	0.181	0.458	CbGaD
Carvedilol—VEGFA—breast cancer	0.0729	0.185	CbGaD
Carvedilol—PTGS1—breast cancer	0.0385	0.0974	CbGaD
Carvedilol—CYP1A1—breast cancer	0.0352	0.0891	CbGaD
Carvedilol—CYP2D6—breast cancer	0.0262	0.0663	CbGaD
Carvedilol—CYP1A1—Toremifene—breast cancer	0.0261	0.0914	CbGbCtD
Carvedilol—XDH—Carboplatin—breast cancer	0.0239	0.0838	CbGbCtD
Carvedilol—CYP3A4—breast cancer	0.0225	0.0569	CbGaD
Carvedilol—ABCB1—breast cancer	0.0187	0.0474	CbGaD
Carvedilol—XDH—Doxorubicin—breast cancer	0.0137	0.048	CbGbCtD
Carvedilol—CYP1A2—Anastrozole—breast cancer	0.0127	0.0446	CbGbCtD
Carvedilol—CYP1A2—Toremifene—breast cancer	0.0116	0.0408	CbGbCtD
Carvedilol—CYP2C9—Anastrozole—breast cancer	0.0115	0.0402	CbGbCtD
Carvedilol—ABCB1—Toremifene—breast cancer	0.0102	0.0357	CbGbCtD
Carvedilol—CYP1A1—Tamoxifen—breast cancer	0.00952	0.0334	CbGbCtD
Carvedilol—CYP3A4—Exemestane—breast cancer	0.0088	0.0308	CbGbCtD
Carvedilol—CYP2C9—Idarubicin—breast cancer	0.00869	0.0305	CbGbCtD
Carvedilol—CYP2D6—Idarubicin—breast cancer	0.00795	0.0279	CbGbCtD
Carvedilol—CYP3A4—Letrozole—breast cancer	0.00748	0.0262	CbGbCtD
Carvedilol—ABCB1—Lapatinib—breast cancer	0.00743	0.026	CbGbCtD
Carvedilol—CYP2E1—Tamoxifen—breast cancer	0.00735	0.0258	CbGbCtD
Carvedilol—CYP2E1—Mitoxantrone—breast cancer	0.00717	0.0251	CbGbCtD
Carvedilol—CYP3A4—Anastrozole—breast cancer	0.00667	0.0234	CbGbCtD
Carvedilol—CYP3A4—Toremifene—breast cancer	0.0061	0.0214	CbGbCtD
Carvedilol—CYP3A4—Fulvestrant—breast cancer	0.00567	0.0199	CbGbCtD
Carvedilol—CYP3A4—Thiotepa—breast cancer	0.00505	0.0177	CbGbCtD
Carvedilol—CYP2C9—Capecitabine—breast cancer	0.00476	0.0167	CbGbCtD
Carvedilol—CYP3A4—Ixabepilone—breast cancer	0.00462	0.0162	CbGbCtD
Carvedilol—CYP3A4—Lapatinib—breast cancer	0.00445	0.0156	CbGbCtD
Carvedilol—CYP1A2—Tamoxifen—breast cancer	0.00425	0.0149	CbGbCtD
Carvedilol—ABCB1—Vinorelbine—breast cancer	0.00412	0.0144	CbGbCtD
Carvedilol—CYP2D6—Vinorelbine—breast cancer	0.00388	0.0136	CbGbCtD
Carvedilol—CYP2C9—Tamoxifen—breast cancer	0.00383	0.0134	CbGbCtD
Carvedilol—ABCB1—Tamoxifen—breast cancer	0.00372	0.013	CbGbCtD
Carvedilol—ABCB1—Mitoxantrone—breast cancer	0.00363	0.0127	CbGbCtD
Carvedilol—SELE—umbilical vein—breast cancer	0.00355	0.0585	CbGeAlD
Carvedilol—CYP2D6—Tamoxifen—breast cancer	0.0035	0.0123	CbGbCtD
Carvedilol—CYP3A4—Raloxifene—breast cancer	0.00337	0.0118	CbGbCtD
Carvedilol—VCAM1—umbilical vein—breast cancer	0.00326	0.0538	CbGeAlD
Carvedilol—ABCB1—Gemcitabine—breast cancer	0.0032	0.0112	CbGbCtD
Carvedilol—CYP1A2—Fluorouracil—breast cancer	0.00313	0.011	CbGbCtD
Carvedilol—CYP2C9—Paclitaxel—breast cancer	0.00298	0.0105	CbGbCtD
Carvedilol—ABCB1—Paclitaxel—breast cancer	0.00289	0.0101	CbGbCtD
Carvedilol—ABCB1—Irinotecan—breast cancer	0.00286	0.01	CbGbCtD
Carvedilol—CYP2C9—Fluorouracil—breast cancer	0.00282	0.0099	CbGbCtD
Carvedilol—ABCB1—Vinblastine—breast cancer	0.00254	0.0089	CbGbCtD
Carvedilol—CYP3A4—Vinorelbine—breast cancer	0.00247	0.00865	CbGbCtD
Carvedilol—CYP2D6—Vinblastine—breast cancer	0.00239	0.00839	CbGbCtD
Carvedilol—CYP3A4—Tamoxifen—breast cancer	0.00223	0.00781	CbGbCtD
Carvedilol—CYP3A4—Mitoxantrone—breast cancer	0.00217	0.00762	CbGbCtD
Carvedilol—ABCB1—Docetaxel—breast cancer	0.00209	0.00734	CbGbCtD
Carvedilol—CYP3A4—Paclitaxel—breast cancer	0.00173	0.00608	CbGbCtD
Carvedilol—CYP3A4—Irinotecan—breast cancer	0.00171	0.006	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—breast cancer	0.00156	0.00547	CbGbCtD
Carvedilol—CYP3A4—Vinblastine—breast cancer	0.00152	0.00533	CbGbCtD
Carvedilol—ABCB1—Methotrexate—breast cancer	0.00151	0.0053	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—breast cancer	0.00147	0.00515	CbGbCtD
Carvedilol—SELE—mammary gland—breast cancer	0.00136	0.0223	CbGeAlD
Carvedilol—CYP3A4—Docetaxel—breast cancer	0.00125	0.0044	CbGbCtD
Carvedilol—SELE—nipple—breast cancer	0.00112	0.0185	CbGeAlD
Carvedilol—VCAM1—nipple—breast cancer	0.00103	0.017	CbGeAlD
Carvedilol—NDUFC2—mammary gland—breast cancer	0.00101	0.0167	CbGeAlD
Carvedilol—HIF1A—nipple—breast cancer	0.000992	0.0164	CbGeAlD
Carvedilol—GJA1—nipple—breast cancer	0.000963	0.0159	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—breast cancer	0.000935	0.00328	CbGbCtD
Carvedilol—NDUFC2—nipple—breast cancer	0.000838	0.0138	CbGeAlD
Carvedilol—HIF1A—embryo—breast cancer	0.000819	0.0135	CbGeAlD
Carvedilol—GJA1—embryo—breast cancer	0.000794	0.0131	CbGeAlD
Carvedilol—SELE—epithelium—breast cancer	0.000755	0.0124	CbGeAlD
Carvedilol—SELE—skin of body—breast cancer	0.000718	0.0118	CbGeAlD
Carvedilol—NPPB—endocrine gland—breast cancer	0.000703	0.0116	CbGeAlD
Carvedilol—VCAM1—epithelium—breast cancer	0.000695	0.0114	CbGeAlD
Carvedilol—HIF1A—epithelium—breast cancer	0.000668	0.011	CbGeAlD
Carvedilol—GJA1—epithelium—breast cancer	0.000648	0.0107	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Fluoxymesterone—breast cancer	0.000648	0.289	CbGdCrCtD
Carvedilol—HIF1A—skin of body—breast cancer	0.000636	0.0105	CbGeAlD
Carvedilol—SELE—uterus—breast cancer	0.000624	0.0103	CbGeAlD
Carvedilol—VCAM1—endometrium—breast cancer	0.000623	0.0103	CbGeAlD
Carvedilol—GJA1—skin of body—breast cancer	0.000617	0.0102	CbGeAlD
Carvedilol—SELE—pituitary gland—breast cancer	0.000613	0.0101	CbGeAlD
Carvedilol—SELE—adipose tissue—breast cancer	0.00061	0.0101	CbGeAlD
Carvedilol—VEGFA—Estradiol—Fulvestrant—breast cancer	0.000609	0.272	CbGdCrCtD
Carvedilol—HIF1A—endometrium—breast cancer	0.000599	0.00987	CbGeAlD
Carvedilol—GJA1—endometrium—breast cancer	0.000581	0.00958	CbGeAlD
Carvedilol—VCAM1—uterus—breast cancer	0.000574	0.00946	CbGeAlD
Carvedilol—NDUFC2—epithelium—breast cancer	0.000564	0.0093	CbGeAlD
Carvedilol—VCAM1—pituitary gland—breast cancer	0.000564	0.00929	CbGeAlD
Carvedilol—VCAM1—adipose tissue—breast cancer	0.000561	0.00925	CbGeAlD
Carvedilol—SELE—female reproductive system—breast cancer	0.000561	0.00924	CbGeAlD
Carvedilol—HIF1A—uterus—breast cancer	0.000552	0.0091	CbGeAlD
Carvedilol—SELE—adrenal gland—breast cancer	0.000547	0.00902	CbGeAlD
Carvedilol—HIF1A—pituitary gland—breast cancer	0.000542	0.00893	CbGeAlD
Carvedilol—HIF1A—adipose tissue—breast cancer	0.00054	0.0089	CbGeAlD
Carvedilol—GJA1—uterus—breast cancer	0.000536	0.00883	CbGeAlD
Carvedilol—GJA1—pituitary gland—breast cancer	0.000526	0.00867	CbGeAlD
Carvedilol—GJA1—adipose tissue—breast cancer	0.000524	0.00863	CbGeAlD
Carvedilol—VCAM1—female reproductive system—breast cancer	0.000516	0.0085	CbGeAlD
Carvedilol—SELE—female gonad—breast cancer	0.00051	0.00841	CbGeAlD
Carvedilol—NDUFC2—endometrium—breast cancer	0.000506	0.00834	CbGeAlD
Carvedilol—VCAM1—adrenal gland—breast cancer	0.000503	0.0083	CbGeAlD
Carvedilol—HIF1A—female reproductive system—breast cancer	0.000496	0.00818	CbGeAlD
Carvedilol—VCAM1—bone marrow—breast cancer	0.000487	0.00803	CbGeAlD
Carvedilol—HIF1A—adrenal gland—breast cancer	0.000484	0.00798	CbGeAlD
Carvedilol—GJA1—female reproductive system—breast cancer	0.000482	0.00793	CbGeAlD
Carvedilol—ADRB3—adipose tissue—breast cancer	0.00048	0.00791	CbGeAlD
Carvedilol—SELE—endocrine gland—breast cancer	0.000475	0.00782	CbGeAlD
Carvedilol—GJA1—adrenal gland—breast cancer	0.00047	0.00774	CbGeAlD
Carvedilol—VCAM1—female gonad—breast cancer	0.000469	0.00774	CbGeAlD
Carvedilol—HIF1A—bone marrow—breast cancer	0.000469	0.00772	CbGeAlD
Carvedilol—NDUFC2—uterus—breast cancer	0.000466	0.00768	CbGeAlD
Carvedilol—VEGFA—endometrium—breast cancer	0.000459	0.00756	CbGeAlD
Carvedilol—NDUFC2—pituitary gland—breast cancer	0.000458	0.00754	CbGeAlD
Carvedilol—NDUFC2—adipose tissue—breast cancer	0.000456	0.00751	CbGeAlD
Carvedilol—GJA1—bone marrow—breast cancer	0.000455	0.00749	CbGeAlD
Carvedilol—HIF1A—female gonad—breast cancer	0.000452	0.00744	CbGeAlD
Carvedilol—ADRB3—female reproductive system—breast cancer	0.000441	0.00727	CbGeAlD
Carvedilol—GJA1—female gonad—breast cancer	0.000438	0.00722	CbGeAlD
Carvedilol—VCAM1—endocrine gland—breast cancer	0.000437	0.00719	CbGeAlD
Carvedilol—VEGFA—uterus—breast cancer	0.000423	0.00697	CbGeAlD
Carvedilol—HIF1A—endocrine gland—breast cancer	0.00042	0.00692	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—breast cancer	0.000419	0.00691	CbGeAlD
Carvedilol—VEGFA—pituitary gland—breast cancer	0.000415	0.00684	CbGeAlD
Carvedilol—VEGFA—adipose tissue—breast cancer	0.000414	0.00682	CbGeAlD
Carvedilol—NDUFC2—adrenal gland—breast cancer	0.000409	0.00674	CbGeAlD
Carvedilol—XDH—endometrium—breast cancer	0.000409	0.00673	CbGeAlD
Carvedilol—GJA1—endocrine gland—breast cancer	0.000407	0.00671	CbGeAlD
Carvedilol—ADRB3—female gonad—breast cancer	0.000402	0.00662	CbGeAlD
Carvedilol—NDUFC2—bone marrow—breast cancer	0.000396	0.00652	CbGeAlD
Carvedilol—NDUFC2—female gonad—breast cancer	0.000381	0.00628	CbGeAlD
Carvedilol—VEGFA—adrenal gland—breast cancer	0.000371	0.00611	CbGeAlD
Carvedilol—VEGFA—bone marrow—breast cancer	0.000359	0.00591	CbGeAlD
Carvedilol—NDUFC2—endocrine gland—breast cancer	0.000355	0.00584	CbGeAlD
Carvedilol—VEGFA—female gonad—breast cancer	0.000346	0.0057	CbGeAlD
Carvedilol—XDH—female reproductive system—breast cancer	0.000338	0.00558	CbGeAlD
Carvedilol—ADRA1D—epithelium—breast cancer	0.000334	0.00551	CbGeAlD
Carvedilol—SELE—lymph node—breast cancer	0.000328	0.00541	CbGeAlD
Carvedilol—GJA1—Progesterone—Fluoxymesterone—breast cancer	0.000317	0.141	CbGdCrCtD
Carvedilol—VCAM1—lymph node—breast cancer	0.000302	0.00497	CbGeAlD
Carvedilol—GJA1—Vinorelbine—Vinblastine—breast cancer	0.000297	0.132	CbGdCrCtD
Carvedilol—HIF1A—lymph node—breast cancer	0.00029	0.00478	CbGeAlD
Carvedilol—XDH—endocrine gland—breast cancer	0.000286	0.00472	CbGeAlD
Carvedilol—GJA1—lymph node—breast cancer	0.000282	0.00464	CbGeAlD
Carvedilol—KCNH2—nipple—breast cancer	0.000275	0.00454	CbGeAlD
Carvedilol—ADRA2C—nipple—breast cancer	0.000272	0.00448	CbGeAlD
Carvedilol—CYP2C9—mammary gland—breast cancer	0.000271	0.00446	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—breast cancer	0.000248	0.00409	CbGeAlD
Carvedilol—NDUFC2—lymph node—breast cancer	0.000245	0.00404	CbGeAlD
Carvedilol—CYP1A2—nipple—breast cancer	0.000236	0.00389	CbGeAlD
Carvedilol—CYP1A1—nipple—breast cancer	0.000233	0.00383	CbGeAlD
Carvedilol—VEGFA—lymph node—breast cancer	0.000222	0.00366	CbGeAlD
Carvedilol—ADRA2A—nipple—breast cancer	0.000217	0.00357	CbGeAlD
Carvedilol—ADRA1D—endocrine gland—breast cancer	0.00021	0.00346	CbGeAlD
Carvedilol—PTGS1—nipple—breast cancer	0.000204	0.00337	CbGeAlD
Carvedilol—ADRB1—adipose tissue—breast cancer	0.000196	0.00323	CbGeAlD
Carvedilol—ADRA1A—epithelium—breast cancer	0.000192	0.00316	CbGeAlD
Carvedilol—ADRB1—female reproductive system—breast cancer	0.00018	0.00297	CbGeAlD
Carvedilol—KCNH2—endometrium—breast cancer	0.000166	0.00274	CbGeAlD
Carvedilol—ADRA2C—endometrium—breast cancer	0.000164	0.0027	CbGeAlD
Carvedilol—Ranolazine—CYP2D6—breast cancer	0.000159	0.153	CrCbGaD
Carvedilol—CYP1A1—epithelium—breast cancer	0.000157	0.00258	CbGeAlD
Carvedilol—ADRA1A—adipose tissue—breast cancer	0.000155	0.00256	CbGeAlD
Carvedilol—Tamsulosin—CYP2D6—breast cancer	0.000153	0.148	CrCbGaD
Carvedilol—KCNH2—uterus—breast cancer	0.000153	0.00253	CbGeAlD
Carvedilol—ADRB1—endocrine gland—breast cancer	0.000153	0.00252	CbGeAlD
Carvedilol—ADRA2C—uterus—breast cancer	0.000151	0.00249	CbGeAlD
Carvedilol—KCNH2—pituitary gland—breast cancer	0.000151	0.00248	CbGeAlD
Carvedilol—CYP1A1—skin of body—breast cancer	0.000149	0.00246	CbGeAlD
Carvedilol—ADRA2C—pituitary gland—breast cancer	0.000149	0.00245	CbGeAlD
Carvedilol—ADRA2C—adipose tissue—breast cancer	0.000148	0.00244	CbGeAlD
Carvedilol—ADRA1A—adrenal gland—breast cancer	0.000139	0.00229	CbGeAlD
Carvedilol—KCNH2—female reproductive system—breast cancer	0.000138	0.00227	CbGeAlD
Carvedilol—PTGS1—epithelium—breast cancer	0.000138	0.00227	CbGeAlD
Carvedilol—Ranolazine—CYP3A4—breast cancer	0.000137	0.131	CrCbGaD
Carvedilol—KCNH2—adrenal gland—breast cancer	0.000134	0.00222	CbGeAlD
Carvedilol—ADRA2C—adrenal gland—breast cancer	0.000133	0.00219	CbGeAlD
Carvedilol—Tamsulosin—CYP3A4—breast cancer	0.000132	0.127	CrCbGaD
Carvedilol—ADRA2A—endometrium—breast cancer	0.000131	0.00216	CbGeAlD
Carvedilol—PTGS1—skin of body—breast cancer	0.000131	0.00216	CbGeAlD
Carvedilol—KCNH2—bone marrow—breast cancer	0.00013	0.00214	CbGeAlD
Carvedilol—CYP1A1—uterus—breast cancer	0.000129	0.00213	CbGeAlD
Carvedilol—CYP1A1—adipose tissue—breast cancer	0.000127	0.00209	CbGeAlD
Carvedilol—KCNH2—female gonad—breast cancer	0.000125	0.00207	CbGeAlD
Carvedilol—ADRA2C—female gonad—breast cancer	0.000124	0.00204	CbGeAlD
Carvedilol—PTGS1—endometrium—breast cancer	0.000123	0.00203	CbGeAlD
Carvedilol—ADRA1A—endocrine gland—breast cancer	0.000121	0.00199	CbGeAlD
Carvedilol—ADRA2A—uterus—breast cancer	0.000121	0.00199	CbGeAlD
Carvedilol—ADRA2A—pituitary gland—breast cancer	0.000118	0.00195	CbGeAlD
Carvedilol—ADRA2A—adipose tissue—breast cancer	0.000118	0.00194	CbGeAlD
Carvedilol—KCNH2—endocrine gland—breast cancer	0.000117	0.00192	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—breast cancer	0.000116	0.00192	CbGeAlD
Carvedilol—PTGS1—uterus—breast cancer	0.000114	0.00187	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—breast cancer	0.000112	0.00185	CbGeAlD
Carvedilol—PTGS1—pituitary gland—breast cancer	0.000112	0.00184	CbGeAlD
Carvedilol—PTGS1—adipose tissue—breast cancer	0.000111	0.00183	CbGeAlD
Carvedilol—ADRA2A—female reproductive system—breast cancer	0.000108	0.00179	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—breast cancer	0.000106	0.00175	CbGeAlD
Carvedilol—CYP1A1—female gonad—breast cancer	0.000106	0.00174	CbGeAlD
Carvedilol—ADRA2A—adrenal gland—breast cancer	0.000106	0.00174	CbGeAlD
Carvedilol—CYP2E1—adrenal gland—breast cancer	0.000104	0.00171	CbGeAlD
Carvedilol—PTGS1—female reproductive system—breast cancer	0.000102	0.00168	CbGeAlD
Carvedilol—CYP1A2—endocrine gland—breast cancer	9.98e-05	0.00164	CbGeAlD
Carvedilol—PTGS1—adrenal gland—breast cancer	9.98e-05	0.00164	CbGeAlD
Carvedilol—ABCB1—embryo—breast cancer	9.97e-05	0.00164	CbGeAlD
Carvedilol—ADRA2A—female gonad—breast cancer	9.87e-05	0.00163	CbGeAlD
Carvedilol—GJA1—Betamethasone—Fluoxymesterone—breast cancer	9.87e-05	0.044	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Fluoxymesterone—breast cancer	9.87e-05	0.044	CbGdCrCtD
Carvedilol—CYP1A1—endocrine gland—breast cancer	9.85e-05	0.00162	CbGeAlD
Carvedilol—CYP2C9—endocrine gland—breast cancer	9.48e-05	0.00156	CbGeAlD
Carvedilol—PTGS1—female gonad—breast cancer	9.3e-05	0.00153	CbGeAlD
Carvedilol—ADRA2A—endocrine gland—breast cancer	9.18e-05	0.00151	CbGeAlD
Carvedilol—CYP2E1—endocrine gland—breast cancer	8.98e-05	0.00148	CbGeAlD
Carvedilol—Propafenone—CYP2D6—breast cancer	8.73e-05	0.084	CrCbGaD
Carvedilol—VEGFA—Betamethasone—Fluoxymesterone—breast cancer	8.7e-05	0.0388	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Fluoxymesterone—breast cancer	8.7e-05	0.0388	CbGdCrCtD
Carvedilol—PTGS1—endocrine gland—breast cancer	8.65e-05	0.00143	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—breast cancer	8.54e-05	0.00141	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—breast cancer	8.4e-05	0.00138	CbGeAlD
Carvedilol—ABCB1—epithelium—breast cancer	8.14e-05	0.00134	CbGeAlD
Carvedilol—KCNH2—lymph node—breast cancer	8.06e-05	0.00133	CbGeAlD
Carvedilol—Propranolol—CYP1A1—breast cancer	8.03e-05	0.0773	CrCbGaD
Carvedilol—ADRA2C—lymph node—breast cancer	7.95e-05	0.00131	CbGeAlD
Carvedilol—CYP2D6—female gonad—breast cancer	7.65e-05	0.00126	CbGeAlD
Carvedilol—Propafenone—CYP3A4—breast cancer	7.49e-05	0.072	CrCbGaD
Carvedilol—ABCB1—endometrium—breast cancer	7.3e-05	0.0012	CbGeAlD
Carvedilol—CYP3A4—endocrine gland—breast cancer	7.23e-05	0.00119	CbGeAlD
Carvedilol—CYP2D6—endocrine gland—breast cancer	7.11e-05	0.00117	CbGeAlD
Carvedilol—CYP1A1—lymph node—breast cancer	6.81e-05	0.00112	CbGeAlD
Carvedilol—ABCB1—uterus—breast cancer	6.72e-05	0.00111	CbGeAlD
Carvedilol—ABCB1—pituitary gland—breast cancer	6.6e-05	0.00109	CbGeAlD
Carvedilol—ABCB1—adipose tissue—breast cancer	6.58e-05	0.00108	CbGeAlD
Carvedilol—ADRA2A—lymph node—breast cancer	6.35e-05	0.00105	CbGeAlD
Carvedilol—Propafenone—ABCB1—breast cancer	6.23e-05	0.06	CrCbGaD
Carvedilol—ABCB1—female reproductive system—breast cancer	6.04e-05	0.000996	CbGeAlD
Carvedilol—PTGS1—lymph node—breast cancer	5.98e-05	0.000985	CbGeAlD
Carvedilol—Propranolol—CYP2D6—breast cancer	5.98e-05	0.0575	CrCbGaD
Carvedilol—ABCB1—adrenal gland—breast cancer	5.9e-05	0.000972	CbGeAlD
Carvedilol—ABCB1—bone marrow—breast cancer	5.71e-05	0.00094	CbGeAlD
Carvedilol—ABCB1—female gonad—breast cancer	5.5e-05	0.000906	CbGeAlD
Carvedilol—Propranolol—CYP3A4—breast cancer	5.13e-05	0.0493	CrCbGaD
Carvedilol—ABCB1—endocrine gland—breast cancer	5.11e-05	0.000843	CbGeAlD
Carvedilol—Propranolol—ABCB1—breast cancer	4.27e-05	0.0411	CrCbGaD
Carvedilol—ABCB1—lymph node—breast cancer	3.54e-05	0.000583	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Capecitabine—breast cancer	1.94e-05	0.000142	CcSEcCtD
Carvedilol—Vomiting—Fluorouracil—breast cancer	1.94e-05	0.000142	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—breast cancer	1.94e-05	0.000142	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—breast cancer	1.94e-05	0.000142	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—breast cancer	1.93e-05	0.000142	CcSEcCtD
Carvedilol—Insomnia—Capecitabine—breast cancer	1.93e-05	0.000141	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—breast cancer	1.92e-05	0.000141	CcSEcCtD
Carvedilol—Rash—Fluorouracil—breast cancer	1.92e-05	0.000141	CcSEcCtD
Carvedilol—Dermatitis—Fluorouracil—breast cancer	1.92e-05	0.000141	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—breast cancer	1.92e-05	0.00014	CcSEcCtD
Carvedilol—Paraesthesia—Capecitabine—breast cancer	1.91e-05	0.00014	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—breast cancer	1.91e-05	0.00014	CcSEcCtD
Carvedilol—Hypersensitivity—Paclitaxel—breast cancer	1.91e-05	0.00014	CcSEcCtD
Carvedilol—Headache—Fluorouracil—breast cancer	1.91e-05	0.00014	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—breast cancer	1.91e-05	0.00014	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—breast cancer	1.91e-05	0.000139	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—breast cancer	1.9e-05	0.000139	CcSEcCtD
Carvedilol—Dyspnoea—Capecitabine—breast cancer	1.9e-05	0.000139	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—breast cancer	1.9e-05	0.000139	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—breast cancer	1.9e-05	0.000139	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—breast cancer	1.9e-05	0.000139	CcSEcCtD
Carvedilol—Nausea—Mitoxantrone—breast cancer	1.89e-05	0.000138	CcSEcCtD
Carvedilol—Nausea—Irinotecan—breast cancer	1.89e-05	0.000138	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—breast cancer	1.89e-05	0.000138	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—breast cancer	1.88e-05	0.000138	CcSEcCtD
Carvedilol—Constipation—Docetaxel—breast cancer	1.88e-05	0.000138	CcSEcCtD
Carvedilol—Pain—Docetaxel—breast cancer	1.88e-05	0.000138	CcSEcCtD
Carvedilol—Back pain—Methotrexate—breast cancer	1.88e-05	0.000138	CcSEcCtD
Carvedilol—Dyspepsia—Capecitabine—breast cancer	1.88e-05	0.000137	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—breast cancer	1.86e-05	0.000136	CcSEcCtD
Carvedilol—Asthenia—Paclitaxel—breast cancer	1.86e-05	0.000136	CcSEcCtD
Carvedilol—Decreased appetite—Capecitabine—breast cancer	1.85e-05	0.000136	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—breast cancer	1.85e-05	0.000135	CcSEcCtD
Carvedilol—Nausea—Gemcitabine—breast cancer	1.84e-05	0.000135	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Capecitabine—breast cancer	1.84e-05	0.000135	CcSEcCtD
Carvedilol—Fatigue—Capecitabine—breast cancer	1.84e-05	0.000135	CcSEcCtD
Carvedilol—Pruritus—Paclitaxel—breast cancer	1.84e-05	0.000135	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—breast cancer	1.83e-05	0.000134	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—breast cancer	1.83e-05	0.000134	CcSEcCtD
Carvedilol—Pain—Capecitabine—breast cancer	1.82e-05	0.000133	CcSEcCtD
Carvedilol—Constipation—Capecitabine—breast cancer	1.82e-05	0.000133	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—breast cancer	1.82e-05	0.000133	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—breast cancer	1.81e-05	0.000133	CcSEcCtD
Carvedilol—Nausea—Fluorouracil—breast cancer	1.81e-05	0.000133	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—breast cancer	1.8e-05	0.000132	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—breast cancer	1.8e-05	0.000132	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—breast cancer	1.8e-05	0.000132	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—breast cancer	1.8e-05	0.000132	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—breast cancer	1.79e-05	0.000131	CcSEcCtD
Carvedilol—Tension—Epirubicin—breast cancer	1.79e-05	0.000131	CcSEcCtD
Carvedilol—Diarrhoea—Paclitaxel—breast cancer	1.78e-05	0.00013	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—breast cancer	1.77e-05	0.000129	CcSEcCtD
Carvedilol—Back pain—Epirubicin—breast cancer	1.76e-05	0.000129	CcSEcCtD
Carvedilol—Feeling abnormal—Capecitabine—breast cancer	1.76e-05	0.000129	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—breast cancer	1.75e-05	0.000128	CcSEcCtD
Carvedilol—Malaise—Methotrexate—breast cancer	1.75e-05	0.000128	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—breast cancer	1.75e-05	0.000128	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—breast cancer	1.75e-05	0.000128	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—breast cancer	1.75e-05	0.000128	CcSEcCtD
Carvedilol—Gastrointestinal pain—Capecitabine—breast cancer	1.74e-05	0.000128	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—breast cancer	1.74e-05	0.000128	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—breast cancer	1.74e-05	0.000127	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—breast cancer	1.74e-05	0.000127	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—breast cancer	1.74e-05	0.000127	CcSEcCtD
Carvedilol—Dizziness—Paclitaxel—breast cancer	1.72e-05	0.000126	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—breast cancer	1.71e-05	0.000126	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—breast cancer	1.71e-05	0.000125	CcSEcCtD
Carvedilol—Cough—Methotrexate—breast cancer	1.7e-05	0.000124	CcSEcCtD
Carvedilol—Urticaria—Capecitabine—breast cancer	1.69e-05	0.000124	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—breast cancer	1.69e-05	0.000124	CcSEcCtD
Carvedilol—Body temperature increased—Capecitabine—breast cancer	1.69e-05	0.000123	CcSEcCtD
Carvedilol—Abdominal pain—Capecitabine—breast cancer	1.69e-05	0.000123	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—breast cancer	1.68e-05	0.000123	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—breast cancer	1.68e-05	0.000123	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—breast cancer	1.68e-05	0.000123	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—breast cancer	1.66e-05	0.000121	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—breast cancer	1.66e-05	0.000121	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—breast cancer	1.66e-05	0.000121	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—breast cancer	1.66e-05	0.000121	CcSEcCtD
Carvedilol—Tension—Doxorubicin—breast cancer	1.65e-05	0.000121	CcSEcCtD
Carvedilol—Vomiting—Paclitaxel—breast cancer	1.65e-05	0.000121	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Malaise—Epirubicin—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Rash—Paclitaxel—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Dermatitis—Paclitaxel—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—breast cancer	1.64e-05	0.00012	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—breast cancer	1.63e-05	0.00012	CcSEcCtD
Carvedilol—Syncope—Epirubicin—breast cancer	1.63e-05	0.000119	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—breast cancer	1.63e-05	0.000119	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—breast cancer	1.63e-05	0.000119	CcSEcCtD
Carvedilol—Headache—Paclitaxel—breast cancer	1.63e-05	0.000119	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—breast cancer	1.62e-05	0.000119	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—breast cancer	1.62e-05	0.000118	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—breast cancer	1.61e-05	0.000118	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—breast cancer	1.6e-05	0.000117	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—breast cancer	1.6e-05	0.000117	CcSEcCtD
Carvedilol—Cough—Epirubicin—breast cancer	1.59e-05	0.000116	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—breast cancer	1.59e-05	0.000116	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—breast cancer	1.59e-05	0.000116	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—breast cancer	1.58e-05	0.000116	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—breast cancer	1.58e-05	0.000115	CcSEcCtD
Carvedilol—Infection—Methotrexate—breast cancer	1.58e-05	0.000115	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—breast cancer	1.57e-05	0.000115	CcSEcCtD
Carvedilol—Hypersensitivity—Capecitabine—breast cancer	1.57e-05	0.000115	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—breast cancer	1.56e-05	0.000114	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—breast cancer	1.56e-05	0.000114	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—breast cancer	1.56e-05	0.000114	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—breast cancer	1.55e-05	0.000114	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—breast cancer	1.55e-05	0.000113	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—breast cancer	1.55e-05	0.000113	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—breast cancer	1.55e-05	0.000113	CcSEcCtD
Carvedilol—Nausea—Paclitaxel—breast cancer	1.54e-05	0.000113	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—breast cancer	1.54e-05	0.000113	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.54e-05	0.000113	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—breast cancer	1.53e-05	0.000112	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—breast cancer	1.53e-05	0.000112	CcSEcCtD
Carvedilol—Asthenia—Capecitabine—breast cancer	1.53e-05	0.000112	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—breast cancer	1.52e-05	0.000111	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—breast cancer	1.52e-05	0.000111	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—breast cancer	1.51e-05	0.000111	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—breast cancer	1.51e-05	0.000111	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—breast cancer	1.51e-05	0.000111	CcSEcCtD
Carvedilol—Pruritus—Capecitabine—breast cancer	1.51e-05	0.00011	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—breast cancer	1.51e-05	0.00011	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—breast cancer	1.51e-05	0.00011	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—breast cancer	1.5e-05	0.00011	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—breast cancer	1.49e-05	0.000109	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—breast cancer	1.49e-05	0.000109	CcSEcCtD
Carvedilol—Oedema—Epirubicin—breast cancer	1.49e-05	0.000109	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—breast cancer	1.48e-05	0.000109	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—breast cancer	1.48e-05	0.000108	CcSEcCtD
Carvedilol—Infection—Epirubicin—breast cancer	1.48e-05	0.000108	CcSEcCtD
Carvedilol—Cough—Doxorubicin—breast cancer	1.47e-05	0.000108	CcSEcCtD
Carvedilol—Shock—Epirubicin—breast cancer	1.46e-05	0.000107	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—breast cancer	1.46e-05	0.000107	CcSEcCtD
Carvedilol—Diarrhoea—Capecitabine—breast cancer	1.46e-05	0.000107	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—breast cancer	1.46e-05	0.000107	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—breast cancer	1.45e-05	0.000106	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—breast cancer	1.45e-05	0.000106	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—breast cancer	1.45e-05	0.000106	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—breast cancer	1.45e-05	0.000106	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—breast cancer	1.44e-05	0.000106	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—breast cancer	1.44e-05	0.000105	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—breast cancer	1.44e-05	0.000105	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—breast cancer	1.43e-05	0.000105	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—breast cancer	1.43e-05	0.000105	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—breast cancer	1.43e-05	0.000105	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—breast cancer	1.42e-05	0.000104	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.42e-05	0.000104	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—breast cancer	1.42e-05	0.000104	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—breast cancer	1.42e-05	0.000104	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—breast cancer	1.41e-05	0.000104	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—breast cancer	1.41e-05	0.000103	CcSEcCtD
Carvedilol—Dizziness—Capecitabine—breast cancer	1.41e-05	0.000103	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—breast cancer	1.4e-05	0.000103	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—breast cancer	1.4e-05	0.000102	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—breast cancer	1.4e-05	0.000102	CcSEcCtD
Carvedilol—Rash—Docetaxel—breast cancer	1.39e-05	0.000102	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—breast cancer	1.39e-05	0.000102	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—breast cancer	1.39e-05	0.000102	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—breast cancer	1.39e-05	0.000101	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—breast cancer	1.38e-05	0.000101	CcSEcCtD
Carvedilol—Headache—Docetaxel—breast cancer	1.38e-05	0.000101	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—breast cancer	1.37e-05	0.000101	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—breast cancer	1.37e-05	0.000101	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—breast cancer	1.37e-05	0.0001	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—breast cancer	1.37e-05	0.0001	CcSEcCtD
Carvedilol—Infection—Doxorubicin—breast cancer	1.37e-05	9.99e-05	CcSEcCtD
Carvedilol—Pain—Methotrexate—breast cancer	1.36e-05	9.93e-05	CcSEcCtD
Carvedilol—Vomiting—Capecitabine—breast cancer	1.36e-05	9.92e-05	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—breast cancer	1.35e-05	9.9e-05	CcSEcCtD
Carvedilol—Shock—Doxorubicin—breast cancer	1.35e-05	9.89e-05	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—breast cancer	1.35e-05	9.85e-05	CcSEcCtD
Carvedilol—Rash—Capecitabine—breast cancer	1.34e-05	9.84e-05	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—breast cancer	1.34e-05	9.83e-05	CcSEcCtD
Carvedilol—Dermatitis—Capecitabine—breast cancer	1.34e-05	9.83e-05	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—breast cancer	1.34e-05	9.82e-05	CcSEcCtD
Carvedilol—Headache—Capecitabine—breast cancer	1.34e-05	9.77e-05	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—breast cancer	1.33e-05	9.77e-05	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—breast cancer	1.33e-05	9.76e-05	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—breast cancer	1.33e-05	9.72e-05	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—breast cancer	1.32e-05	9.69e-05	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—breast cancer	1.32e-05	9.66e-05	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—breast cancer	1.31e-05	9.59e-05	CcSEcCtD
Carvedilol—Nausea—Docetaxel—breast cancer	1.31e-05	9.57e-05	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—breast cancer	1.31e-05	9.57e-05	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—breast cancer	1.31e-05	9.57e-05	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—breast cancer	1.3e-05	9.5e-05	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—breast cancer	1.29e-05	9.45e-05	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—breast cancer	1.28e-05	9.4e-05	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—breast cancer	1.28e-05	9.38e-05	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—breast cancer	1.28e-05	9.37e-05	CcSEcCtD
Carvedilol—Pain—Epirubicin—breast cancer	1.27e-05	9.29e-05	CcSEcCtD
Carvedilol—Constipation—Epirubicin—breast cancer	1.27e-05	9.29e-05	CcSEcCtD
Carvedilol—Nausea—Capecitabine—breast cancer	1.27e-05	9.27e-05	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—breast cancer	1.26e-05	9.23e-05	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—breast cancer	1.25e-05	9.18e-05	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—breast cancer	1.25e-05	9.18e-05	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.25e-05	9.16e-05	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—breast cancer	1.24e-05	9.1e-05	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—breast cancer	1.23e-05	9.03e-05	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—breast cancer	1.23e-05	8.97e-05	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—breast cancer	1.22e-05	8.96e-05	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—breast cancer	1.22e-05	8.94e-05	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—breast cancer	1.21e-05	8.89e-05	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—breast cancer	1.21e-05	8.85e-05	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—breast cancer	1.19e-05	8.74e-05	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—breast cancer	1.19e-05	8.68e-05	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—breast cancer	1.18e-05	8.67e-05	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—breast cancer	1.18e-05	8.63e-05	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—breast cancer	1.18e-05	8.6e-05	CcSEcCtD
Carvedilol—Pain—Doxorubicin—breast cancer	1.18e-05	8.6e-05	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—breast cancer	1.17e-05	8.59e-05	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—breast cancer	1.17e-05	8.59e-05	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—breast cancer	1.17e-05	8.56e-05	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—breast cancer	1.14e-05	8.33e-05	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—breast cancer	1.13e-05	8.29e-05	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—breast cancer	1.12e-05	8.22e-05	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—breast cancer	1.12e-05	8.22e-05	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—breast cancer	1.09e-05	8.01e-05	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—breast cancer	1.09e-05	7.99e-05	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—breast cancer	1.09e-05	7.95e-05	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—breast cancer	1.09e-05	7.95e-05	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—breast cancer	1.09e-05	7.95e-05	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—breast cancer	1.07e-05	7.8e-05	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—breast cancer	1.05e-05	7.69e-05	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—breast cancer	1.05e-05	7.68e-05	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—breast cancer	1.02e-05	7.44e-05	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—breast cancer	1.01e-05	7.41e-05	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—breast cancer	1.01e-05	7.38e-05	CcSEcCtD
Carvedilol—Rash—Methotrexate—breast cancer	1e-05	7.32e-05	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—breast cancer	1e-05	7.32e-05	CcSEcCtD
Carvedilol—Headache—Methotrexate—breast cancer	9.94e-06	7.28e-05	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—breast cancer	9.86e-06	7.22e-05	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—breast cancer	9.82e-06	7.19e-05	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—breast cancer	9.72e-06	7.12e-05	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—breast cancer	9.44e-06	6.91e-05	CcSEcCtD
Carvedilol—Nausea—Methotrexate—breast cancer	9.43e-06	6.9e-05	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—breast cancer	9.4e-06	6.88e-05	CcSEcCtD
Carvedilol—Rash—Epirubicin—breast cancer	9.36e-06	6.85e-05	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—breast cancer	9.35e-06	6.85e-05	CcSEcCtD
Carvedilol—Headache—Epirubicin—breast cancer	9.3e-06	6.81e-05	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—breast cancer	9.09e-06	6.65e-05	CcSEcCtD
Carvedilol—Nausea—Epirubicin—breast cancer	8.82e-06	6.46e-05	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—breast cancer	8.74e-06	6.39e-05	CcSEcCtD
Carvedilol—Rash—Doxorubicin—breast cancer	8.66e-06	6.34e-05	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—breast cancer	8.66e-06	6.34e-05	CcSEcCtD
Carvedilol—Headache—Doxorubicin—breast cancer	8.61e-06	6.3e-05	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—breast cancer	8.16e-06	5.97e-05	CcSEcCtD
Carvedilol—CYP2C9—Metabolism—CAV1—breast cancer	5.52e-07	4.62e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—breast cancer	5.51e-07	4.62e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAF1—breast cancer	5.5e-07	4.6e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—breast cancer	5.49e-07	4.6e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1A1—breast cancer	5.48e-07	4.59e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK8—breast cancer	5.48e-07	4.59e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—breast cancer	5.48e-07	4.59e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HSP90AA1—breast cancer	5.48e-07	4.59e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—breast cancer	5.47e-07	4.59e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RELA—breast cancer	5.47e-07	4.58e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—breast cancer	5.47e-07	4.58e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	5.44e-07	4.56e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ERCC2—breast cancer	5.44e-07	4.56e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—breast cancer	5.44e-07	4.55e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—breast cancer	5.42e-07	4.54e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—breast cancer	5.41e-07	4.53e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—breast cancer	5.4e-07	4.52e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—breast cancer	5.4e-07	4.52e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—breast cancer	5.38e-07	4.51e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—breast cancer	5.37e-07	4.5e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	5.36e-07	4.49e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MTOR—breast cancer	5.36e-07	4.49e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	5.35e-07	4.49e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—breast cancer	5.33e-07	4.47e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NCOA1—breast cancer	5.33e-07	4.46e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	5.32e-07	4.45e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SRC—breast cancer	5.31e-07	4.45e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—breast cancer	5.3e-07	4.44e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.27e-07	4.42e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SRC—breast cancer	5.26e-07	4.41e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—breast cancer	5.25e-07	4.4e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—STK11—breast cancer	5.25e-07	4.4e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP19A1—breast cancer	5.25e-07	4.4e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	5.23e-07	4.38e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—breast cancer	5.23e-07	4.38e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—breast cancer	5.22e-07	4.37e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—breast cancer	5.21e-07	4.37e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SRC—breast cancer	5.2e-07	4.35e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK8—breast cancer	5.19e-07	4.35e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—breast cancer	5.18e-07	4.34e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—breast cancer	5.17e-07	4.33e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—breast cancer	5.16e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—breast cancer	5.16e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—breast cancer	5.15e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	5.14e-07	4.31e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—breast cancer	5.13e-07	4.3e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—breast cancer	5.12e-07	4.29e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—breast cancer	5.12e-07	4.29e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—breast cancer	5.12e-07	4.29e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—breast cancer	5.11e-07	4.28e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—breast cancer	5.11e-07	4.28e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—breast cancer	5.11e-07	4.28e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK8—breast cancer	5.11e-07	4.28e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAF1—breast cancer	5.11e-07	4.28e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—breast cancer	5.09e-07	4.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RELA—breast cancer	5.08e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—breast cancer	5.08e-07	4.25e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—breast cancer	5.07e-07	4.25e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—breast cancer	5.06e-07	4.24e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—breast cancer	5.05e-07	4.23e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	5.03e-07	4.22e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—breast cancer	5.03e-07	4.21e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—breast cancer	5.01e-07	4.2e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MTOR—breast cancer	4.98e-07	4.18e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	4.98e-07	4.18e-06	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	4.98e-07	4.17e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—breast cancer	4.93e-07	4.13e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—breast cancer	4.93e-07	4.13e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SRC—breast cancer	4.92e-07	4.12e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—breast cancer	4.9e-07	4.11e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—breast cancer	4.9e-07	4.1e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—COMT—breast cancer	4.88e-07	4.09e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—breast cancer	4.86e-07	4.07e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—breast cancer	4.85e-07	4.06e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SRC—breast cancer	4.84e-07	4.06e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—breast cancer	4.83e-07	4.05e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—breast cancer	4.8e-07	4.02e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—breast cancer	4.79e-07	4.02e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HMOX1—breast cancer	4.79e-07	4.01e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—breast cancer	4.79e-07	4.01e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—breast cancer	4.79e-07	4.01e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—breast cancer	4.79e-07	4.01e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ITPR1—breast cancer	4.78e-07	4e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—breast cancer	4.76e-07	3.99e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—breast cancer	4.76e-07	3.99e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	4.76e-07	3.98e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—breast cancer	4.75e-07	3.98e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—breast cancer	4.74e-07	3.97e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—breast cancer	4.73e-07	3.96e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—breast cancer	4.73e-07	3.96e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—breast cancer	4.72e-07	3.95e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAV1—breast cancer	4.71e-07	3.95e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—breast cancer	4.71e-07	3.95e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—breast cancer	4.71e-07	3.94e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	4.68e-07	3.92e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—breast cancer	4.67e-07	3.91e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—breast cancer	4.67e-07	3.91e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—breast cancer	4.66e-07	3.91e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—breast cancer	4.66e-07	3.9e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—breast cancer	4.66e-07	3.9e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	4.65e-07	3.89e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—breast cancer	4.65e-07	3.89e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—breast cancer	4.64e-07	3.88e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	4.63e-07	3.88e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—breast cancer	4.61e-07	3.87e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—breast cancer	4.6e-07	3.85e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—breast cancer	4.58e-07	3.84e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—breast cancer	4.58e-07	3.84e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—breast cancer	4.56e-07	3.82e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—breast cancer	4.56e-07	3.82e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK8—breast cancer	4.54e-07	3.8e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—breast cancer	4.53e-07	3.8e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—breast cancer	4.52e-07	3.79e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—breast cancer	4.52e-07	3.78e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.5e-07	3.77e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—breast cancer	4.47e-07	3.75e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—breast cancer	4.47e-07	3.74e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—breast cancer	4.47e-07	3.74e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NCOR1—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—breast cancer	4.46e-07	3.74e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—breast cancer	4.46e-07	3.73e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—breast cancer	4.45e-07	3.73e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	4.44e-07	3.72e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	4.42e-07	3.7e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—breast cancer	4.42e-07	3.7e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—breast cancer	4.41e-07	3.69e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—breast cancer	4.4e-07	3.69e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—breast cancer	4.4e-07	3.69e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—breast cancer	4.4e-07	3.68e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—breast cancer	4.36e-07	3.65e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—breast cancer	4.36e-07	3.65e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—breast cancer	4.34e-07	3.63e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—breast cancer	4.33e-07	3.63e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—breast cancer	4.33e-07	3.62e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	4.32e-07	3.62e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—breast cancer	4.31e-07	3.61e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—breast cancer	4.31e-07	3.61e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—breast cancer	4.3e-07	3.61e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SRC—breast cancer	4.3e-07	3.6e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—breast cancer	4.29e-07	3.6e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—breast cancer	4.29e-07	3.6e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—breast cancer	4.27e-07	3.58e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—breast cancer	4.24e-07	3.55e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1A1—breast cancer	4.23e-07	3.55e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK8—breast cancer	4.21e-07	3.53e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—breast cancer	4.21e-07	3.53e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—breast cancer	4.2e-07	3.52e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ERCC2—breast cancer	4.2e-07	3.52e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—breast cancer	4.19e-07	3.51e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—breast cancer	4.17e-07	3.5e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—breast cancer	4.15e-07	3.47e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—breast cancer	4.12e-07	3.45e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—breast cancer	4.1e-07	3.44e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—breast cancer	4.08e-07	3.42e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—breast cancer	4.07e-07	3.41e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	4.04e-07	3.39e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—breast cancer	4.01e-07	3.36e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	4.01e-07	3.36e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SRC—breast cancer	3.99e-07	3.35e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—breast cancer	3.96e-07	3.32e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	3.95e-07	3.31e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—breast cancer	3.94e-07	3.31e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—breast cancer	3.93e-07	3.29e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—breast cancer	3.91e-07	3.28e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.89e-07	3.26e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—breast cancer	3.88e-07	3.25e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—breast cancer	3.87e-07	3.25e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—breast cancer	3.85e-07	3.23e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.85e-07	3.23e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—breast cancer	3.85e-07	3.23e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—breast cancer	3.85e-07	3.22e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—breast cancer	3.84e-07	3.22e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—breast cancer	3.83e-07	3.2e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—breast cancer	3.82e-07	3.2e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—breast cancer	3.78e-07	3.16e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.77e-07	3.16e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	3.74e-07	3.13e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—breast cancer	3.74e-07	3.13e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—breast cancer	3.73e-07	3.12e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—breast cancer	3.71e-07	3.1e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	3.68e-07	3.08e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—breast cancer	3.68e-07	3.08e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—breast cancer	3.66e-07	3.06e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—breast cancer	3.65e-07	3.06e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—breast cancer	3.65e-07	3.06e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAV1—breast cancer	3.64e-07	3.05e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—breast cancer	3.63e-07	3.04e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—breast cancer	3.62e-07	3.04e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—breast cancer	3.62e-07	3.03e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—breast cancer	3.58e-07	3e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—breast cancer	3.58e-07	3e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3.57e-07	2.99e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—breast cancer	3.57e-07	2.99e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—breast cancer	3.56e-07	2.98e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—breast cancer	3.56e-07	2.98e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—breast cancer	3.56e-07	2.98e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—breast cancer	3.55e-07	2.97e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—breast cancer	3.5e-07	2.93e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—breast cancer	3.5e-07	2.93e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—breast cancer	3.46e-07	2.9e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—breast cancer	3.41e-07	2.85e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—breast cancer	3.36e-07	2.81e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—breast cancer	3.34e-07	2.8e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—breast cancer	3.33e-07	2.79e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—breast cancer	3.31e-07	2.78e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—breast cancer	3.31e-07	2.78e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—breast cancer	3.31e-07	2.77e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—breast cancer	3.3e-07	2.77e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—breast cancer	3.29e-07	2.76e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—breast cancer	3.27e-07	2.74e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	3.27e-07	2.74e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—breast cancer	3.26e-07	2.73e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—breast cancer	3.26e-07	2.73e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—breast cancer	3.23e-07	2.71e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—breast cancer	3.16e-07	2.65e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—breast cancer	3.15e-07	2.64e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—breast cancer	3.06e-07	2.56e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	3.04e-07	2.55e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—breast cancer	3.03e-07	2.54e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—breast cancer	3.01e-07	2.52e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—breast cancer	2.97e-07	2.49e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—breast cancer	2.94e-07	2.46e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—breast cancer	2.91e-07	2.44e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—breast cancer	2.9e-07	2.43e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—breast cancer	2.88e-07	2.41e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—breast cancer	2.84e-07	2.38e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.81e-07	2.36e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—breast cancer	2.75e-07	2.31e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—breast cancer	2.73e-07	2.28e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—breast cancer	2.69e-07	2.25e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.67e-07	2.24e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—breast cancer	2.57e-07	2.15e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—breast cancer	2.54e-07	2.13e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—breast cancer	2.52e-07	2.11e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—breast cancer	2.51e-07	2.11e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.48e-07	2.08e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—breast cancer	2.37e-07	1.98e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—breast cancer	2.35e-07	1.97e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—breast cancer	2.19e-07	1.84e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—breast cancer	2.05e-07	1.72e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—breast cancer	2.01e-07	1.68e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—breast cancer	1.93e-07	1.62e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—breast cancer	1.92e-07	1.61e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—breast cancer	1.64e-07	1.37e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—breast cancer	1.55e-07	1.3e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—breast cancer	1.26e-07	1.06e-06	CbGpPWpGaD
